Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MASP2 | O00187 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4676678 | 1.00 | MASP2 (0.53) | MASP2SLC2A1EPHX2PNMTOPRM1 | |
| SCHEMBL4679395 | 0.84 | ANPEP (0.58) | EPHX2OPRM1OPRL1CARM1PRMT6 | |
| SCHEMBL4676327 | 0.84 | ANPEP (0.58) | EPHX2OPRM1OPRL1CARM1PRMT6 | |
| SCHEMBL4677304 | 0.83 | MEN1 (0.60) | EPHX2KMT2ACARM1PRMT6 | |
| SCHEMBL4677340 | 0.83 | MEN1 (0.60) | EPHX2KMT2ACARM1PRMT6 | |
| SCHEMBL4676692 | 0.83 | SMN1; SMN2 (0.53) | GAAKMT2A | |
| SCHEMBL4676219 | 0.83 | SMN1; SMN2 (0.53) | GAAKMT2A | |
| SCHEMBL12311006 | 0.80 | MASP2 (0.59) | MASP2SLC2A1PNMTRXFP1 | |
| SCHEMBL12864453 | 0.79 | ERCC1 (0.58) | MASP2SLC2A1KMT2ARXFP1 | |
| SCHEMBL8302088 | 0.78 | ERCC1 (0.62) | CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | claimed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | claimed |
| EP-1633702-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-15 | — | — | EP | claimed |
| WO-2004106289-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-09 | — | — | WO | claimed |
| EP-1975153-A2 | Protease inhibitors | Prozymex A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | disclosed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155803-A1 | Protease inhibitors | DPP7, DPP9, DPP3 | MASP2 135/4885SLC2A1 464/4885EPHX2 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.